Squamous Cell Carcinoma of the Head and Neck Clinical Trial
Official title:
Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck
Tobacco and alcohol are the two major risk factors for upper respiratory tract cancer (VADS).
Tobacco and alcohol are the two major risk factors for upper respiratory tract cancer (VADS).
Among patients with VADS cancer, more than 60% reported daily alcohol consumption of more
than 20 g / d. Such poisoning can be harmful, causing histological lesions of alcoholic liver
disease, such as steatosis, alcoholic hepatitis, liver fibrosis and cirrhosis. In a
population consuming more than 50 g of alcohol per day for 5 years, the prevalence of severe
hepatic fibrosis is between 30% and 40%. In the therapeutic management of a cancer of VADS,
the presence of cirrhosis is a prognostic element, increasing the postoperative risk of
haemorrhage, surgical site infection and acute renal failure. The search for cirrhosis in the
pre-therapeutic assessment is therefore important. The diagnosis of cirrhosis is not a
problem when clinical, biological, radiological or endoscopic signs of hepatic insufficiency
or portal hypertension are present. Asymptomatic cirrhosis is more difficult to diagnose
without liver biopsy. Noninvasive hepatic exploration techniques have recently been developed
and validated for the evaluation of liver fibrosis in the context of alcoholic liver disease.
Fibroscan® (Echosens, Paris, France) is an imaging device for measuring the liver hardness
(hepatic elasticity expressed in kPa), with a strong correlation with the presence of
histological fibrosis of the liver. At the threshold of 19.5 kPa, Fibroscan can be used to
diagnose cirrhosis with good diagnostic performance (Se 80%, Sp 90%, VPP 93%, VPN 70%) and
good inter- and intra-observer reproducibility. Elastometry is a simple, reliable and
non-invasive tool to systematically evaluate hepatic fibrosis in patients with VADS cancer.
The examination can be performed during a routine care consultation. The post-therapeutic
morbidity induced by cirrhosis in the cancers of VADS is not well known and there is no
recommendation in France about the hepatic explorations to be carried out during the initial
assessment of these neoplasias. It is essential to be able to specify this morbidity in order
to adapt if necessary the therapeutic strategy of cancers of VADS.
The objective of this study is to systematically determine the presence of cirrhosis and / or
liver fibrosis in patients with VADS cancer, in order to investigate their impact on the
morbidity after treatment of squamous cell carcinomas of the head and neck.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
| Recruiting |
NCT06236464 -
Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas
|
||
| Terminated |
NCT04659369 -
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
|
Phase 1 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT02572778 -
Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer
|
||
| Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
| Terminated |
NCT01488318 -
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT00999700 -
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin
|
Phase 3 | |
| Completed |
NCT02565758 -
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02543476 -
SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
|
N/A | |
| Recruiting |
NCT03938012 -
Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma
|
||
| Terminated |
NCT02124850 -
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
|
Phase 1 | |
| Active, not recruiting |
NCT03313804 -
Priming Immunotherapy in Advanced Disease With Radiation
|
Phase 2 | |
| Recruiting |
NCT05208762 -
A Study of SGN-PDL1V in Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT04453046 -
Hemopurifier Plus Pembrolizumab in Head and Neck Cancer
|
N/A | |
| Completed |
NCT01758731 -
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
|
Phase 1 | |
| Completed |
NCT02473731 -
A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
|
Phase 1 | |
| Completed |
NCT02022098 -
Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial
|
N/A | |
| Completed |
NCT01458392 -
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Completed |
NCT02882308 -
Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.
|
Phase 2 |